SCHEMBL3335856

SCHEMBL3335856

[O]C(c1cccc(F)c1F)C1CCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.40
CES1 P23141 2/20 0.40
EPHX1 P07099 1/20 0.36
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
BCHE P06276 1/20 0.33
HPGD P15428 1/20 0.33
CXCR2 P25025 2/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
C3AR1 Q16581 1/20 0.32
XIAP P98170 2/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
NOS3 P29474 2/20 0.31
NOS1 P29475 2/20 0.31
NOS2 P35228 2/20 0.31
HDAC4 P56524 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3338397 0.84 CES2 (0.39) CES2CES1ALDH1A1NOS3NOS1
SCHEMBL3337740 0.71 CES2 (0.40) CES2CES1POLBGAA
SCHEMBL17874168 0.70 EPHX1 (0.39) CES2CES1EPHX1MEN1KMT2A
SCHEMBL17874163 0.70 EPHX1 (0.34) CES2CES1EPHX1
SCHEMBL3310094 0.68 CES2 (0.46) CES2CES1BCHEALDH1A1CYP2C9
Hydrochloric Acid SCHEMBL16825346 0.67 SLC6A2 (0.39)
SCHEMBL1036600 0.67 EPHX1 (0.38) CES2CES1EPHX1MEN1KMT2A
SCHEMBL9437111 0.67 KMT2A (0.47) CES2CES1EPHX1MEN1KMT2A
SCHEMBL9437113 0.67 KMT2A (0.38) CES2CES1EPHX1MEN1KMT2A
SCHEMBL1600457 0.66 CES2 (0.44) CES2CES1BCHEALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 CES2 1256/4885CES1 1748/4885EPHX1 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.